BioWorld

Feb. 14, 2003

Epimmune Plans Acquisition Of Anosys For Synergistic Platform

The San Diego-based company entered a preliminary merger agreement with Anosys Inc. to create a combined entity focused on immunotherapeutics and products to treat cancer and infectious diseases. (BioWorld Today) Read More

RAC Says Stopping Trials With Retroviral Vectors Not Warranted

Trans-Atlantic Genomic Search For Leprosy Susceptibility Gene Heats Up Over Chromosomal Candidates

Albany Molecular Expands Via Lilly Deal, Organichem Purchase

Holiday Notice

Correction

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 28, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 28, 2026.

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...